- All Patients Treated with INGREZZA® (valbenazine) Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therapeutic Dose Within Six Months
- Findings Presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting
SAN DIEGO, March 31, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from a real-world study showing that all patients with tardive dyskinesia achieved a therapeutic dose with INGREZZA® (valbenazine) capsules upon initiation of treatment. This retrospective cohort study will be presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting in Houston, Texas.
"These findings provide critical insights into the real-world use of VMAT2 inhibitors in treating tardive dyskinesia," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "Significant differences were observed between INGREZZA and deutetrabenazine in reaching therapeutic doses. The data showed INGREZZA provides a therapeutic dose from day one, without the need for titration, potentially reducing the clinician and patient burden associated with sub-therapeutic dosing."
The retrospective cohort study used data from IQVIA's longitudinal prescription and professional fee claims U.S. databases (2022-2024). The study included 3,527 patients who began treatment with INGREZZA, 2,166 patients who began treatment with deutetrabenazine twice daily (BID) and 326 who began treatment with deutetrabenazine extended release (XR). Patients were assessed over a six-month baseline period and a six-month follow-up period.
Throughout the six-month follow-up period, patients experienced dose changes according to their treatment needs in the course of real-world clinical practice. Therapeutic dosing threshold was defined as the lowest dose showing clinical efficacy per controlled clinical trial data (deutetrabenazine 24 mg/day and INGREZZA 40 mg/day). Results showed:
- All patients treated with INGREZZA at 40 mg, 60 mg or 80 mg reached a therapeutic dose upon initiation of treatment, while significantly fewer deutetrabenazine-treated patients were able to reach a therapeutic dose within six months.
- Only 47.5% of patients on deutetrabenazine BID and 54.3% of patients on deutetrabenazine XR were able to reach a therapeutic dose within six months, with an average attainment time of three to four weeks (P45 days (INGREZZA: n=1,856; deutetrabenazine BID: n=1,007; deutetrabenazine XR: n=126). Results showed:
- Fewer patients taking INGREZZA experienced a dose change when compared with those taking deutetrabenazine.
- Significantly more deutetrabenazine-treated patients had a change in dose after the first month of treatment compared with INGREZZA (INGREZZA: 33.7%; BID: 48.1%; XR: 54.0%; P
- Fewer patients taking INGREZZA experienced a dose change when compared with those taking deutetrabenazine.